Bain goes big again, leading $350M round to fund oral challenger to blockbuster asthma biologics Game on, Hemlibra. Novo Nordisk's attempt to snatch Roche's hemophilia crown gets serious An Epic in miniature: CRISPR pioneer's startup reels in $55M to use tiny Cas for epigenetic engineering Sponsored: Ramp up your AAV production with Lonza’s HEK 293 cell line and patented vectors technologies Genentech rides up to 2nd target in Bicycle immuno-oncology collab Sponsored: Decentralized clinical trials, patient experience and the role of supply chain management Aldeyra's dry eye drops make another clinical splash as the company nears NDA submission Tenaya tackles genetic heart condition after thorough screening process nails down target Roche hands over $55M for licensing rights to Ionis’ kidney disease candidate Noncommercial sponsors need more support, says ASCO winner Clinscience Brace yourself, Amgen. Lumakras' sales might disappoint as key data readouts draw near, analyst warns Moderna's omicron booster triggers stronger response against subvariants than its original shot, company says Sanofi, still on CEO Paul Hudson's quest to slim down, offloads 17 brands to Neuraxpharm Business Group: These are employers' key concerns following Supreme Court abortion ruling Featured Story | By Nick Paul Taylor Bain Capital Life Sciences is at it again. Biotech’s go-to source for big-ticket financing rounds has stepped up to lead a $350 million series A round in Areteia Therapeutics, positioning the newly created startup to run phase 3 trials of an asthma candidate designed to have biologiclike efficacy in an oral dosage form. read more |
| |
|---|
|
Top Stories By James Waldron Hemlibra’s days as the hemophilia head honcho may be numbered. At least, that seems to be the hope of Novo Nordisk, which released back-to-back trial data for two of its own assets for the bleeding disorder over the past few days. read more By Nick Paul Taylor CRISPR co-inventor Stanley Qi is out with a new biotech that wants to make a big splash by going small. The startup, Epic Bio, corralled a VC syndicate willing to bet $55 million on its vision to use the smallest known Cas protein in epigenetic engineering. read more Sponsored by: Lonza AG Advance your AAV-based therapeutics by leveraging Lonza expertise, using the same tools and technologies used for our platform processes. Balance risk and speed, while maintaining high AAV productivity read more By James Waldron Roche’s Genentech unit called in an option to license a second immuno-oncology target from its collaboration with British biotech Bicycle. read more Sponsored by: Parexel The rise of clinical trial complexity has been well-documented but the impact on logistics is not well understood. Here, we look at decentralized trials, patient experience and the role of logistics. read more By Max Bayer Aldeyra's dry eye med has notched another clinical win as the company nears a formal approval submission. The biotech is slated to meet with regulators in the third quarter. read more By Max Bayer Tenaya is touting a thorough target-screening process involving deep learning that's helped the company to develop a preclinical med to treat a genetic heart disease. The company plans to ask regulators later this year for a thumbs-up to take the med into phase 1 trials. read more By Gabrielle Masson Roche is handing over $55 million for the licensing rights to Ionis Pharmaceuticals’ rare kidney disease treatment candidate, an investigational med that the Big Pharma will advance into a phase 3 clinical trial. read more By Gareth Macdonald A study by the Polish Myeloma Consortium and the University of Chicago set new standards for blood cancer therapy, according to judges at the American Society of Clinical Oncology. read more By Angus Liu Amgen’s first-in-class KRAS inhibitor Lumakras has been grabbing attention even before its approval. Now, after closely watching the drug’s commercial performance in non-small cell lung cancer, one team of analysts is sounding an alarm ahead of key clinical trial data readouts. read more By Zoey Becker Just a few weeks after the FDA recommended that vaccine makers update their boosters to protect against Omicron, Moderna unveiled positive data showing high neutralizing antibody responses in its updated booster trial. read more By Fraiser Kansteiner Sanofi has entered a deal to hand over 17 branded products to central nervous system specialist Neuraxpharm for an undisclosed sum. The drugs comprise two product portfolios for CNS disorders, pain and vascular diseases, Neuraxpharm said in a release. read more By Paige Minemyer In the wake of the Supreme Court's ruling last month that reversed abortion protections under Roe v. Wade, employers are pushing the feds to quickly address potential volatility in health benefits. read more Resources Sponsored by: Triangle Insights Group, LLC Discover how the new partnership between TrialCard and Triangle Insights Group can help you bridge the critical gap between strategy and execution, ensuring commercialization success of your product or therapy. Sponsored by: Nexelis Discover Nexelis’ first-hand perspective on how to develop innovative, agile solutions in vaccine efficacy testing in this exclusive e-book. Sponsored by: Lumanity Check out our 22 on-demand panels, featuring 100+ speakers. Tap into discussions of scientific progress in oncology around development, regulatory, clinical, commercial and investment perspectives. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting For an emerging biopharma company, Europe can be very attractive. But it can also be complex and confusing. This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Decentralized Clinical Trials Forum July 26, 2022 | Free Virtual Event Fierce Biotech Summit September 19-20, 2022 | Boston, MA Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Health Payer Forum October 12, 2022 | Free Virtual Event Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Decentralized Clinical Trials Summit: Part of the Fierce Clinical Collective Oct 24-26, 2022 | Philadelphia, PA | Presented by: Fierce Pharma Clinical Quality Oversight Forum: Part of the Fierce Clinical Collective Oct 24-26, 2022 | Philadelphia PA | Presented by: Fierce Pharma Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Diversity, Equity & Inclusion Forum November 15-16, 2022 | Free Virtual Event Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual Fierce Clinical Trial Billing & Research Compliance Summit February 2023 | Location TBD Fierce BD&L Summit for Life Sciences March 14-15, 2023 | San Francisco, CA | 